Condition: Early-stage Breast Cancer · Sponsor: Ottawa Hospital Research Institute
The goal of this randomized, pragmatic clinical trial is to evaluate the omission of granulocyte colony-stimulating factors (G-CSF) in breast cancer patients receiving paclitaxel portion of dose-dense adriamycin-cyclophosphamide and paclitaxel (DD-AC/T) chemotherapy. Participants will be randomized to either take G-CSF while on the paclitaxel portion of DD-AC/T chemotherapy or to omit G-CSF while on the paclitaxel portion of DD-AC/T chemotherapy.
This description comes directly from the study's public registry record.
Lisa Vandermeer, MSc · 613-737-7700 · lvandermeer@ohri.ca
Carol Stober · 613-737-7700 · cstober@toh.ca
Always discuss trial participation with your own doctor first.
| Kingston Health Sciences Centre | Kingston, Ontario, Canada | Recruiting |
| Lakeridge Health | Oshawa, Ontario, Canada | Recruiting |
| The Ottawa Hospital Cancer Centre | Ottawa, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05753618